News stories about Arsanis (NASDAQ:ASNS) have trended somewhat positive this week, according to Accern Sentiment. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Arsanis earned a media sentiment score of 0.06 on Accern’s scale. Accern also gave media coverage about the company an impact score of 45.7796441463147 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the headlines that may have effected Accern Sentiment Analysis’s scoring:
- Arsanis Inc (ASNS) Given Consensus Rating of “Strong Buy” by Analysts (americanbankingnews.com)
- Arsanis (ASNS) Announces Quarterly Earnings Results, Misses Expectations By $0.82 EPS (americanbankingnews.com)
- Arsanis (ASNS) Given a $26.00 Price Target by Cantor Fitzgerald Analysts (americanbankingnews.com)
- Arsanis Reports Financial Results and Highlights for Fourth Quarter and Full Year 2017 (finance.yahoo.com)
- Zacks: Analysts Expect Arsanis Inc (ASNS) to Announce -$3.05 EPS (americanbankingnews.com)
Arsanis (NASDAQ:ASNS) traded down $0.21 during midday trading on Wednesday, hitting $22.54. The company had a trading volume of 32,766 shares, compared to its average volume of 19,231. Arsanis has a 12 month low of $10.40 and a 12 month high of $25.25.
A number of research analysts have recently issued reports on the company. Cantor Fitzgerald set a $26.00 price objective on Arsanis and gave the company a “buy” rating in a research note on Friday, March 9th. ValuEngine raised Arsanis from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. Citigroup assumed coverage on Arsanis in a research note on Monday, December 11th. They set a “buy” rating and a $27.00 price objective on the stock. Cowen assumed coverage on Arsanis in a research note on Monday, December 11th. They set an “outperform” rating on the stock. Finally, Piper Jaffray Companies assumed coverage on Arsanis in a research note on Monday, December 11th. They set an “overweight” rating and a $23.00 price objective on the stock. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $25.33.
COPYRIGHT VIOLATION WARNING: This report was first reported by BBNS and is the sole property of of BBNS. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://baseballnewssource.com/2018/03/14/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-arsanis-asns-share-price/2028872.html.
Arsanis Company Profile
Arsanis, Inc is a biopharmaceutical company. The Company is focused on the discovering and developing monoclonal antibodies (mAbs) for the targeted immunotherapy of serious infections. The Company’s mAbs focus on specific pathogens and pathogenic processes. Its product pipeline includes ASN100, ASN200, ASN300, ASN400 and ASN500.
Receive News & Ratings for Arsanis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arsanis and related companies with MarketBeat.com's FREE daily email newsletter.